Researchers at the University of California, San Francisco have published findings indicating that psilocybin, a classic psychedelic compound, may help combat inflammation and support cellular health in humans. The study, appearing Wednesday in JAMA Psychiatry, examined blood markers in a small group of patients with Parkinson’s disease before and after receiving psilocybin treatments.
The research team measured five signaling molecules associated with inflammation in study participants at baseline and following two psilocybin sessions. Results showed substantially reduced inflammation levels after treatment, with these improvements remaining evident a month later. Additionally, a blood marker indicating mitochondrial stress showed marked improvement immediately following psilocybin administration, though longer-term benefits on this measure were less clear.
The findings emerged from a pilot study of 12 participants evaluating the safety and feasibility of administering psilocybin to people with Parkinson’s disease, a population typically excluded from psychedelic research trials due to safety considerations. The original study, conducted last year, established a reassuring safety profile and suggested potential symptom improvements among participants.
Researchers acknowledge significant study limitations, including the absence of a control group and participants’ awareness of receiving the active drug. Dr. Ellen Bradley and colleagues emphasize that the blood-level findings require confirmation through additional research before drawing definitive conclusions. However, they note that objective biological markers changed measurably over time, warranting continued investigation into how psychedelics may address conditions involving inflammation and mitochondrial dysfunction.
The implications extend beyond Parkinson’s disease, with researchers suggesting potential applications for depression, anxiety, and cardio-metabolic disorders. Independent experts note the significance of testing anti-inflammatory effects in actual disease populations rather than healthy volunteers, representing a meaningful step in validating pharmacological research conducted over the past fifteen years.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI